What is the clinical evidence from this study?

Study design: Other. Population: Diabetic Cardiomyopathy (n=60). Intervention: Cyclovirobuxine D (CVB-D) vs. Saline (DCM model control). Primary outcome: Cardiac dysfunction and cardiomyocyte pyroptosis.

July 5, 2022Open Access

Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis via NLRP3 in vivo and in vitro

GGGe GaoChina Geological Survey LFLingyun FuGuiyang Medical University YXYini XuKunming University of Science and Technology

Key Result

Cyclovirobuxine D ameliorated experimental diabetic cardiomyopathy by inhibiting cardiomyocyte pyroptosis via the NLRP3 pathway in vivo and in vitro.

PICO

Population

Diabetic Cardiomyopathy (n=60)

Intervention / Comparator

Cyclovirobuxine D (CVB-D) vs Saline (DCM model control) (0.5 mg/kg/day or 1 mg/kg/day)

Primary Outcome

Cardiac dysfunction and cardiomyocyte pyroptosis

Abstract

NLRP3, providing a novel molecular target for CVB-D clinical application.

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Cite This Study

Gao et al. (Tue,) conducted a other in Diabetic Cardiomyopathy (n=60). Cyclovirobuxine D (CVB-D) vs. Saline (DCM model control) was evaluated on Cardiac dysfunction and cardiomyocyte pyroptosis. Cyclovirobuxine D ameliorated experimental diabetic cardiomyopathy by inhibiting cardiomyocyte pyroptosis via the NLRP3 pathway in vivo and in vitro.

synapsesocial.com/papers/6a07b50015d371b38838692d https://doi.org/https://doi.org/10.3389/fphar.2022.906548